We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Mark Bullimore

Mark A Bullimore MCOptom, PhD, FAAO

Adjunct Professor, University of Houston, College of Optometry, Houston, Texas

Professor Bullimore received his Optometry degree and PhD in Vision Science from Aston University in Birmingham, England. He was a Professor at The Ohio State University College of Optometry for 15 years and previously spent 8 years at the University of California at Berkeley. He is an Adjunct Professor at the University of Houston College of Optometry.

His research interests include myopia, low vision, presbyopia, and refractive surgery. He received grants from the National Eye Institute to study adult myopia progression and several training grants.

He is a Fellow of the American Academy of Optometry and a Gold Fellow of the Association for Research in Vision and Ophthalmology. He is former President and Development Director of the American Optometric Foundation, a philanthropic organization devoted to the advancement of optometric education and research. He is Associate Editor of Ophthalmic and Physiological Optics and the former Editor of Optometry and Vision Science.

He served a four-year term on the U.S. Food and Drug Administration’s Ophthalmic Devices Panel and is a regulatory consultant for a number of ophthalmic, surgical, and pharmaceutical companies.

Disclosures

Dr. Bullimore is a paid consultant for Alcon, CooperVision, Essilor of America, Eyenovia, Genentech, jCyte, J&J Vision, Novartis, Paragon Vision Sciences, and Tearfilm Innovations.